Common stock, $0.001 par value per share
- Symbol
- LAB
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 5.02, 5.07, 7.01, 9.01 · 8-K
LABNASDAQEQUITYCurrent
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As disclosed in Item 5.07 of this Current Report on Form 8-K, at the Special Meeting (as defined below), the stockholders of Standard BioTools Inc.…
Standard BioTools Inc. (NASDAQ: LAB) is committed to setting the new standard in the life science tools industry through strategic consolidation, best-in-class operations and a world-class management team. The Company's established portfolio includes essential, standardized next-generation solutions designed to help biomedical researchers develop better therapeutics faster. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn and YouTube™.
Standard BioTools Inc. · 8-K · Filed 2026-11-19
Exhibit 99.1 Standard BioTools Stockholders Approve All Proposals Related to Merger with Treeline Biosciences and Sale of Mass Cytometry Business BOSTON, Mass., Nov. 19, 2026 - Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools” or the “Company”) today announced that, at its Special Meeting of Stockholders held earlier today, stockholders approved all proposals related to the Company’s previously announced merger with Treeline Biosciences, Inc. (“Treeline”) and the sale of its Mass Cytometry business to Element Biosystems, LLC, an acquisition vehicle formed by GMT Venture Partners, LLC. “We are pleased with the outcome of today’s vote and thank our stockholders for their support of these transactions,” said Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools. “These approvals represent an important step toward completing our planned merger with Treeline and positioning our Mass Cytometry business for continued success under new ownership. We look forward to completing both transactions.” The merger with Treeline is expected to close in the fourth quarter of 2026, subject to the satisfaction of remaining customary closing conditions. The sale o…
Open exhibit ↗